Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.

Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB.

Mol Cancer Ther. 2019 Nov 19. pii: molcanther.0183.2019. doi: 10.1158/1535-7163.MCT-19-0183. [Epub ahead of print]

PMID:
31744895
2.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
3.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0552-3. [Epub ahead of print] No abstract available.

PMID:
31455850
4.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.

Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.

PMID:
29059158
5.

Incidence of Postoperative Pain after Single Visit and Two Visit Root Canal Therapy: A Randomized Controlled Trial.

Patil AA, Joshi SB, Bhagwat SV, Patil SA.

J Clin Diagn Res. 2016 May;10(5):ZC09-12. doi: 10.7860/JCDR/2016/16465.7724. Epub 2016 May 1.

6.

Identification of druggable cancer driver genes amplified across TCGA datasets.

Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV, Buchanan S, Peng SB, Staschke KA, Yadav V, Yue Y, Kouros-Mehr H.

PLoS One. 2014 May 29;9(5):e98293. doi: 10.1371/journal.pone.0098293. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107646.

7.

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.

Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14.

8.

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2092-7. doi: 10.1016/j.bmcl.2011.01.139. Epub 2011 Feb 3.

PMID:
21353551
9.

Novel inhibitors of mTORC1 and mTORC2.

Bhagwat SV, Crew AP.

Curr Opin Investig Drugs. 2010 Jun;11(6):638-45. Review.

PMID:
20496258
10.

Non-templated hydrothermal growth of anisotropic magnetite nanostructures using hexamine as the directing agent.

Bhagwat SV, Jouen S, Kundaliya DC, Singh H, Jagadale T, Athawale AA, Lofland S, Hannoyer B, Ogale SB.

J Nanosci Nanotechnol. 2009 Oct;9(10):5823-8.

PMID:
19908459
11.

High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay.

Bhagwat SV, Kahler J, Yao Y, Maresca P, Brooks M, Crew A, Boisclair M, Pachter JA.

Assay Drug Dev Technol. 2009 Oct;7(5):471-8. doi: 10.1089/adt.2008.0183.

PMID:
19895344
12.

Invasive cervical resorption: a case report.

Hiremath H, Yakub SS, Metgud S, Bhagwat SV, Kulkarni S.

J Endod. 2007 Aug;33(8):999-1003. Epub 2007 Apr 2.

PMID:
17878092
13.
14.

Flavin-containing monooxygenase activity in camel tissues: comparison with rat and human liver enzymes.

Raza H, Bhagwat SV, John A.

Comp Biochem Physiol C Toxicol Pharmacol. 2004 Dec;139(4):289-93.

PMID:
15683840
15.

CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells.

Petrovic N, Bhagwat SV, Ratzan WJ, Ostrowski MC, Shapiro LH.

J Biol Chem. 2003 Dec 5;278(49):49358-68. Epub 2003 Sep 24.

17.

The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis.

Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH.

Blood. 2003 Mar 1;101(5):1818-26. Epub 2002 Oct 24.

PMID:
12406907
18.

Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter.

Mullick J, Anandatheerthavarada HK, Amuthan G, Bhagwat SV, Biswas G, Camasamudram V, Bhat NK, Reddy SE, Rao V, Avadhani NG.

J Biol Chem. 2001 May 25;276(21):18007-17. Epub 2001 Feb 21.

19.

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.

Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH.

Blood. 2001 Feb 1;97(3):652-9.

20.
21.

Cloning, characterisation and bacterial expression of full length cDNA for the mouse liver microsomal glutathione S-transferase.

Raza H, Mullick J, John A, Bhagwat SV, Avadhani NG.

Oncol Rep. 2000 May-Jun;7(3):645-9.

PMID:
10767383
22.

Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria.

Bhagwat SV, Boyd MR, Ravindranath V.

Biochem Pharmacol. 2000 Mar 1;59(5):573-82.

PMID:
10660123
23.

Dual targeting property of the N-terminal signal sequence of P4501A1. Targeting of heterologous proteins to endoplasmic reticulum and mitochondria.

Bhagwat SV, Biswas G, Anandatheerthavarada HK, Addya S, Pandak W, Avadhani NG.

J Biol Chem. 1999 Aug 20;274(34):24014-22.

24.

Constitutive and inducible cytochromes P450 in rat lung mitochondria: xenobiotic induction, relative abundance, and catalytic properties.

Bhagwat SV, Mullick J, Raza H, Avadhani NG.

Toxicol Appl Pharmacol. 1999 May 1;156(3):231-40.

PMID:
10222315
25.
27.

Differential response of cytosolic, microsomal, and mitochondrial glutathione S-transferases to xenobiotic inducers.

Bhagwat SV, Mullick J, Avadhani NG, Raza H.

Int J Oncol. 1998 Aug;13(2):281-8.

PMID:
9664123
28.

Targeting of NH2-terminal-processed microsomal protein to mitochondria: a novel pathway for the biogenesis of hepatic mitochondrial P450MT2.

Addya S, Anandatheerthavarada HK, Biswas G, Bhagwat SV, Mullick J, Avadhani NG.

J Cell Biol. 1997 Nov 3;139(3):589-99.

29.

Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain.

Bhagwat SV, Bhamre S, Boyd MR, Ravindranath V.

Neuropsychopharmacology. 1996 Aug;15(2):133-42.

30.

Further characterization of rat brain flavin-containing monooxygenase. Metabolism of imipramine to its N-oxide.

Bhagwat SV, Bhamre S, Boyd MR, Ravindranath V.

Biochem Pharmacol. 1996 Jun 14;51(11):1469-75.

PMID:
8630088
31.

Xenobiotic metabolism in brain.

Ravindranath V, Bhamre S, Bhagwat SV, Anandatheerthavarada HK, Shankar SK, Tirumalai PS.

Toxicol Lett. 1995 Dec;82-83:633-8. Review.

PMID:
8597120
32.
33.

Brain mitochondrial cytochromes P450: xenobiotic metabolism, presence of multiple forms and their selective inducibility.

Bhagwat SV, Boyd MR, Ravindranath V.

Arch Biochem Biophys. 1995 Jun 20;320(1):73-83.

PMID:
7793987
34.

Rat brain cytochrome P450. Reassessment of monooxygenase activities and cytochrome P450 levels.

Bhagwat SV, Boyd MR, Ravindranath V.

Drug Metab Dispos. 1995 Jun;23(6):651-4.

PMID:
7587947
35.

Cancer profile in Surat and its vicinity.

Gadhia PK, Panchal ND, Bhagwat SV.

J Indian Med Assoc. 1995 Mar;93(3):101-2.

PMID:
8522804
36.

Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes.

Bhamre S, Bhagwat SV, Shankar SK, Boyd MR, Ravindranath V.

Brain Res. 1995 Feb 20;672(1-2):276-80.

PMID:
7749747
37.

Cerebral flavin-containing monooxygenase-mediated metabolism of antidepressants in brain: immunochemical properties and immunocytochemical localization.

Bhamre S, Bhagwat SV, Shankar SK, Williams DE, Ravindranath V.

J Pharmacol Exp Ther. 1993 Oct;267(1):555-9.

PMID:
8229786
38.

Catalytic activity and immunohistochemical localization of flavin-containing monooxygenase in rat kidney.

Bhamre S, Shankar SK, Bhagwat SV, Ravindranath V.

Life Sci. 1993;52(20):1601-7.

PMID:
8483388
39.

Comparative study of bacterial flora in infected nonvital human dental pulp with periapical pathosis.

Bhagwat SV.

Dent Dialogue. 1974;1(4):11-6. No abstract available.

PMID:
4534540
40.

Comparison of antibacterial action of Milton's solution with mysteclin-V solution in infected root canal therapy.

Bhagwat SV.

J Indian Dent Assoc. 1973 Jan;45(1):14-23. No abstract available.

PMID:
4514882
41.

Explosive incidence of heat stroke in poultry.

Bhagwat SV, Kadhane DL.

Indian Vet J. 1968 Nov;45(11):971-2. No abstract available.

PMID:
5752796
42.

A comparative study of the beta-glucuronidase activity of the whole saliva in cases with and without oral leukoplakia.

Sanjana MK, Mehta FS, Bhagwat SV, Shroff BC.

J All India Dent Assoc. 1965 Jul;37(7):219-23. No abstract available.

PMID:
5213147

Supplemental Content

Loading ...
Support Center